Literature DB >> 26577457

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.

Rachael Hough1, Robert Danby2, Nigel Russell3, David Marks4, Paul Veys5, Bronwen Shaw6, Rob Wynn7, Ajay Vora8, Stephen Mackinnon9, Karl S Peggs1, Charles Crawley10, Charlie Craddock11, Antonio Pagliuca12, Gordon Cook13, John A Snowden14, Andrew Clark15, Judith Marsh12, Sergio Querol16,17, Guy Parkes18, Henny Braund16, Vanderson Rocha19.   

Abstract

Allogeneic haemopoietic stem cell transplantation offers a potentially curative treatment option for a wide range of life-threatening malignant and non-malignant disorders of the bone marrow and immune system in patients of all ages. With rapidly emerging advances in the use of alternative donors, such as mismatched unrelated, cord blood and haploidentical donors, it is now possible to find a potential donor for almost all patients in whom an allograft is indicated. Therefore, for any specific patient, the transplant physician may be faced with a myriad of potential choices, including decisions concerning which donor to prioritize where there is more than one, the optimal selection of specific umbilical cord blood units and which conditioning and graft-versus-host disease prophylactic schedule to use. Donor choice may be further complicated by other important factors, such as urgency of transplant, the presence of alloantibodies, the disease status (homozygosity or heterozygosity) of sibling donors affected by inherited disorders and the cytomegalovirus serostatus of patient and donor. We report UK consensus guidelines on the selection of umbilical cord blood units, the hierarchy of donor selection and the preferred conditioning regimens for umbilical cord blood transplantation, with a summary of rationale supporting these recommendations.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  haematological malignancies; paediatric haematology; stem cell transplantation; umbilical cord blood

Mesh:

Year:  2015        PMID: 26577457     DOI: 10.1111/bjh.13802

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation.

Authors:  Junya Kanda; Katsutsugu Umeda; Koji Kato; Makoto Murata; Junichi Sugita; Souichi Adachi; Katsuyoshi Koh; Maiko Noguchi; Hiroaki Goto; Nao Yoshida; Maho Sato; Yuhki Koga; Tsukasa Hori; Yuko Cho; Atsushi Ogawa; Masami Inoue; Yoshiko Hashii; Yoshiko Atsuta; Takanori Teshima
Journal:  Bone Marrow Transplant       Date:  2020-03-11       Impact factor: 5.483

2.  CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking.

Authors:  Juliet N Barker; Jane Kempenich; Joanne Kurtzberg; Claudio G Brunstein; Colleen Delaney; Filippo Milano; Ioannis Politikos; Elizabeth J Shpall; Andromachi Scaradavou; Jason Dehn
Journal:  Blood Adv       Date:  2019-04-23

3.  Cord blood attached segment: is this a relevant quality control to predict a good hematopoietic stem cell graft?

Authors:  L Faivre; H Boucher; R Zerbib; T Domet; A Desproges; C Couzin; V Vanneaux; J Larghero; A Cras
Journal:  Bone Marrow Transplant       Date:  2017-07-10       Impact factor: 5.483

4.  Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Authors:  P Rettman; F Malard; N Legrand; O Avinens; J-F Eliaou; C Picard; A Dormoy; X Lafarge; M de Matteis; A Kennel; P Loiseau; A Devys; A Boudifa; L Absi; M Fort; D Masson; F Quainon; I Theodorou; A Batho; A Parissiadis; F Delbos; M Drouet; D Senitzer; E Marry; N Raus; I Yakoub-Agha; A Cesbron; C Retière; K Gagne
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

Review 5.  From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.

Authors:  Roni Shouval; Arnon Nagler
Journal:  Stem Cell Investig       Date:  2017-05-24

6.  Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Authors:  Sarah Anand; Samantha Thomas; Kelly Corbet; Cristina Gasparetto; Gwynn D Long; Richard Lopez; Ashley K Morris; David A Rizzieri; Keith M Sullivan; Anthony D Sung; Stefanie Sarantopoulos; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

7.  Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.

Authors:  Akira Nishimura; Yuki Aoki; Yasuyoshi Ishiwata; Takuya Ichimura; Junichi Ueyama; Yuta Kawahara; Takahiro Tomoda; Maiko Inoue; Kazuaki Matsumoto; Kento Inoue; Haruka Hiroki; Shintaro Ono; Motoi Yamashita; Tsubasa Okano; Mari Tanaka-Kubota; Miho Ashiarai; Satoshi Miyamoto; Reiji Miyawaki; Chika Yamagishi; Mari Tezuka; Teppei Okawa; Akihiro Hoshino; Akifumi Endo; Masato Yasuhara; Takahiro Kamiya; Noriko Mitsuiki; Toshiaki Ono; Takeshi Isoda; Masakatsu Yanagimachi; Daisuke Tomizawa; Masayuki Nagasawa; Shuki Mizutani; Michiko Kajiwara; Masatoshi Takagi; Hirokazu Kanegane; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2021-02-01       Impact factor: 8.317

8.  Factors Predicting the Presence of Maternal Cells in Cord Blood and Associated Changes in Immune Cell Composition.

Authors:  Marina El Haddad; Karlin R Karlmark; Xavier-Côme Donato; Gabriel V Martin; Florence Bretelle; Nathalie Lesavre; Jean-François Cocallemen; Marielle Martin; Christophe Picard; Jean Roudier; Raoul Desbriere; Nathalie C Lambert
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

9.  Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC).

Authors:  Hanadi Rafii; Federico Garnier; Annalisa Ruggeri; Irina Ionescu; Caroline Ballot; Danièle Bensoussan; Christian Chabannon; Bernard Dazey; John De Vos; Eric Gautier; Christine Giraud; Jérome Larghero; Audrey Cras; Valérie Mialou; Virginie Persoons; Fabienne Pouthier; Jean-Baptiste Thibert; Jean-Hugues Dalle; Gerard Michel; Chantal Kenzey; Fernanda Volt; Vanderson Rocha; Jacques-Olivier Bay; Marie-Thérèse Rubio; Catherine Faucher; Evelyne Marry; Eliane Gluckman
Journal:  Bone Marrow Transplant       Date:  2021-05-14       Impact factor: 5.483

10.  Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy.

Authors:  Paraskevi Diamanti; Charlotte V Cox; Benjamin C Ede; Robert A Uger; John P Moppett; Allison Blair
Journal:  Blood Adv       Date:  2021-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.